Ignazio Martellucci

Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients

Cirino Botta, Vito Barbieri, Domenico Ciliberto et al. · Cancer Biology & Therapy · 2013 · 92 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial)

Pierpaolo Correale, Pierosandro Tagliaferri, Antonella Fioravanti et al. · Clinical Cancer Research · 2008 · 76 citations · Full text

Medicine, Immunology, Oncology +17

A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients

Pierpaolo Correale, Daniela Cerretani, Cinzia Remondo et al. · Oncology Reports · 2006 · 56 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients

Pierpaolo Correale, Cirino Botta, Marco Pagliuchi et al. · Cancer Biology & Therapy · 2011 · 37 citations · Full text

Medicine, Oncology, Pharmacology +13

Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer

Roberto Petrioli, Pamela Torre, Guido Pesola et al. · Journal of Geriatric Oncology · 2019 · 34 citations · Full text

Medicine, Geriatric Medicine, Oncology +13